Compass Pathways (NASDAQ: CMPS) has recently received a number of price target changes and ratings updates:
- 8/16/2026 – Compass Pathways was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 8/8/2026 – Compass Pathways was downgraded by Wall Street Zen from “hold” to “strong sell”.
- 8/7/2026 – Compass Pathways had its price target lowered by HC Wainwright from $70.00 to $65.00. They now have a “buy” rating on the stock.
- 8/6/2026 – Compass Pathways had its price target raised by Morgan Stanley from $17.00 to $18.00. They now have an “overweight” rating on the stock.
- 8/6/2026 – Compass Pathways had its price target lowered by Royal Bank Of Canada from $22.00 to $21.00. They now have an “outperform” rating on the stock.
- 8/6/2026 – Compass Pathways had its price target raised by B. Riley Financial, Inc. from $17.00 to $22.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Compass Pathways had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
- 7/27/2026 – Compass Pathways is now covered by Wells Fargo & Company. They set an “equal weight” rating and a $13.00 price target on the stock.
- 7/27/2026 – Compass Pathways is now covered by Wells Fargo & Company. They set an “equal weight” rating and a $13.00 price target on the stock.
- 7/17/2026 – Compass Pathways had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/8/2026 – Compass Pathways had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
- 7/8/2026 – Compass Pathways was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $21.00 price target on the stock.
- 7/7/2026 – Compass Pathways had its price target raised by Stifel Nicolaus from $14.00 to $21.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Compass Pathways had its “outperform” rating reaffirmed by Wolfe Research.
- 7/7/2026 – Compass Pathways was given a new $25.00 price target by Compass Point.
- 7/7/2026 – Compass Pathways had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $20.00 price target on the stock.
- 7/7/2026 – Compass Pathways had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
- 7/7/2026 – Compass Pathways had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $17.00 price target on the stock.
- 7/7/2026 – Compass Pathways had its price target raised by BTIG Research from $14.00 to $25.00. They now have a “buy” rating on the stock.
- 6/26/2026 – Compass Pathways had its price target raised by Canaccord Genuity Group Inc. from $18.00 to $20.00. They now have a “buy” rating on the stock.
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
Featured Stories
- Five stocks we like better than Compass Pathways
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Compass Pathways PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
